Tr1X

Biotechnology Research • 4242 Campus Point Ct, Suite 500, United States • 21-50 Employees

Company overview

Headquarters	4242 Campus Point Ct, Suite 500, San Diego, California 92121, US
Phone number	+18582554447
Website	tr1x.bio
NAICS	541714
Keywords	Biotechnology, Research, Immunotherapy, Cell Therapy, Immunology, Genetic Engineering, Autoimmune Disease, Tolerance, T Cells, Inflammatory Disease
Employees	21-50
Socials

Key Contacts at Tr1X

David De Vries

Co-Founder & Chief Operating Officer

Yannick Bulliard

Senior Program Director

Lyndsey Young

Executive Director, Quality

Jonathan Perrin

Co-Founder; General Counsel; Executive Director Of Operations

Ryan Bjordahl

Senior Director, Biology

Linda Mclaughlin

Head Of Human Resources, Executive Director

Muhi Davis

Executive Director, Clinical Operations

Jennifer Fan

Director Of Analytical Sciences

Tr1X Email Formats

Tr1X uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@tr1x.bio), used 93.9% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@tr1x.bio	93.9%
{first initial}{last name}	jdoe@tr1x.bio	6.1%

About Tr1X

Tr1X is a private, clinical-stage biotechnology company focused on developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory diseases. Founded by industry experts, including the scientists who discovered Type 1 regulatory T (Tr1) cells, the company is developing a pipeline of off-the-shelf allogeneic cell therapies for autoimmune diseases with high unmet medical need. Our TRX cells are designed to mimic the function of naturally occurring Tr1 cells, which work to restore immune tolerance, stopping severe autoimmune and inflammatory disease in its tracks. Tr1X is the first company ever to use an allogeneic engineered Tr1 cell therapy in clinical trials. Tr1X is headquartered in San Diego, CA. For more information, please visit www.tr1x.bio.

Tr1X revenue & valuation

Annual revenue	$37,500,000
Revenue per employee	$915,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$120,000,000
Total funding	$83,000,000